Tag Archives: copyright

What Does 2016 Hold In Store For Pharma ETFs

The pharma sector has been in the middle of a controversy, with questions being raised about the high prices of drugs. Democratic presidential frontrunner Hillary Clinton’s “price gouging” tweet triggered a slide in healthcare stocks in September. While there have always been concerns regarding the pricing and affordability of prescription drugs, the issue is back in focus following a 5000% price hike implemented by Turing Pharmaceuticals for Daraprim (pyrimethamine) that was approved by the FDA way back in 1953. (Read: 16 Bold ETF Predictions for 2016 ) Other companies like Valeant (NYSE: VRX ) are also under review for significantly hiking the prices of acquired drugs. Irrespective of who wins the presidential race, drug pricing will remain a topic of discussion among policymakers, the media and the general public. Meanwhile, mergers, acquisitions and deals continue to take center stage in the pharma sector. While 2014 turned out to be one of the most active years in the pharma sector where mergers and acquisitions (M&As) and licensing agreements are concerned, the trend continued this year as well. Small bolt-on acquisitions, in-licensing activities and collaborations for the development of pipeline candidates will also continue especially in therapeutic areas like central nervous system disorders, diabetes and immunology/inflammation. The hepatitis C virus market is also attracting a lot of attention. (Read: Top Sectors of 2016 and Their Leading ETFs ) Another lucrative area is immuno-oncology as these therapies have the potential to change the treatment paradigm for cancer — they basically use the natural capability of the patient’s own immune system to fight the cancer. Major players in this field include Bristol-Myers (NYSE: BMY ), AstraZeneca (NYSE: AZN ), Merck (NYSE: MRK ) and Roche. Deals targeting immuno-oncology are being inked by companies like Pfizer (NYSE: PFE ), Merck KGaA ( OTCPK:MKGAY ), Bristol-Myers, AstraZeneca and Incyte (NASDAQ: INCY ). Another trend being witnessed is the divestment of non-core business segments. Companies like Pfizer, UCB ( OTCPK:UCBJY ), Novartis (NYSE: NVS ), Glaxo (NYSE: GSK ) and AstraZeneca have all been a part of this trend. The monetization of non-core assets allows these companies to focus on their areas of expertise. Restructuring activities are also gaining momentum as large pharma companies are looking to cut costs and streamline their operations. Most of these companies are re-evaluating their pipelines and discontinuing programs which do not have a favorable risk-benefit profile. Swapping of businesses is another activity that could pick pace in 2016. Biosimilars are also a focus area. Pfizer’s acquisition of Hospira gives it a strong position in the biosimilars market. Companies like Merck and Novartis are involved in the development of biosimilars as well – in fact, Novartis’ Sandoz was the first company to launch a biosimilar in the U.S. New products are steadily gaining traction and contributing significantly to sales and so far in 2015, the FDA has approved 43 new molecular entities (NMEs) and biological products. Some of the important new product approvals this year include Vertex’s cystic fibrosis treatment, Orkambi, Pfizer’s cancer treatment, Ibrance, Novartis’ psoriasis treatment, Cosentyx, PCSK9 inhibitors – Amgen’s (NASDAQ: AMGN ) Repatha and Sanofi (NYSE: SNY )/Regeneron’s (NASDAQ: REGN ) Praluent, Roche’s advanced melanoma treatment, Cotellic and Gilead’s (NASDAQ: GILD ) Genvoya (HIV). Pharma ETFs in Focus Highlighted below are some pharma ETFs – ETFs present a low-cost and convenient way to get a diversified exposure to the sector. PowerShares Dynamic Pharmaceuticals Portfolio ETF (NYSEARCA: PJP ) PJP, launched in Jun 2005 by Invesco PowerShares, tracks the Dynamic Pharmaceuticals Intellidex Index. The fund covers health care stocks. The top 3 holdings include Bristol-Myers Squibb (5.22%), Eli Lilly & Co. (NYSE: LLY ) (5.16%) and Johnson & Johnson (NYSE: JNJ ) (5.13%). The total assets of the fund as of Dec 15, 2015 were $1,691.5 million representing 23 holdings. The fund’s expense ratio is 0.56% while dividend yield is 0.47%. The trading volume is roughly 135,985 shares per day. SPDR S&P Pharmaceuticals ETF (NYSEARCA: XPH ) XPH, launched in Jun 2006, tracks the S&P Pharmaceuticals Select Industry Index. This ETF primarily covers pharma stocks (99.39%) with the top 3 holdings being Intra-Cellular Therapies, Inc. ( OTCQB:ITCI ) (4.84%), Nektar Therapeutics (NASDAQ: NKTR ) (3.69%), and Bristol-Myers Squibb (3.44%). Total assets as of Dec 15, 2015 were $695.6 million representing 41 holdings. The fund’s expense ratio is 0.35% and dividend yield is 0.71%. The trading volume is roughly 65,529 shares per day. iShares U.S. Pharmaceuticals ETF (NYSEARCA: IHE ) IHE, launched in May 2006, seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index. The fund mainly consists of pharma companies (87%). Biotech companies account for about 10.6% of the fund. The top 3 holdings of this fund are Johnson & Johnson (10.79%), Pfizer (8.70%) and Bristol-Myers Squibb (7.84%). The total assets of the fund as of Dec 16, 2015 were $890.45 million representing 43 holdings. The fund’s expense ratio is 0.45% with the dividend yield being 0.89%. The trading volume is roughly 28,951 shares per day. Market Vectors Pharmaceutical ETF (NYSEARCA: PPH ) PPH was launched in Dec 2011 and tracks the Market Vectors U.S. Listed Pharmaceutical 25 Index. The top 3 holdings of this fund are large-cap pharma companies – Johnson & Johnson (7.97%), Novartis (7.02%) and Bristol-Myers Squibb (5.55%). The total assets as of Dec 16, 2015 were $335.9 million representing 26 holdings. While the expense ratio is 0.35%, dividend yield is 2.04%. The trading volume is roughly 72,694 shares per day. Conclusion While EU austerity measures, negative currency impact and pricing pressure remain headwinds, the pharma industry is out of the worst of its genericization phase. Many companies, which had faced generic headwinds in the last couple of years, should continue to see a sustained improvement in results this year. Cost-cutting, downsizing, emerging markets and new products should support growth. Increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector. Link to the original article on Zacks.com

Do ETFs Cause Market Volatility?

My colleague Russ Koesterich has said it before: Market volatility is the new normal. And when markets are volatile, we see volatility in the prices of exchange traded funds (ETFs). Some investors may wonder if the ETF is simply showing us the market volatility, or if it is actually causing it. Let’s take a closer look. We know that ETFs trade on the open market. Let’s pretend that we’re monitoring an ETF that is listed in the US but invests in Asian stocks. If we buy that ETF and keep an eye on its price when the Asian market is closed, we can see that the price of the ETF still moves throughout the day, even though the Asian market is closed. That’s because news and information in the U.S. and European markets impacts the value of Asian market stocks, and thus the ETF that holds those stocks. When the Asian market opens again, we see the local stocks move to reflect this new information, and the ETF’s price realigns with the local market. We call this “price discovery”-the ETF is showing you where the market should be priced at a given point in time, even if that market is closed. If all markets are open at the same time, this form of price discovery generally doesn’t take place. ETFs and Market Volatility ETFs by nature have created entries into the market that investors wouldn’t normally have otherwise. Some speculate that now more investors have access to markets, there is more trading, and this can actually cause market volatility. We’ve done a lot of research on this and found that ETFs do not cause market volatility. Instead, their price fluctuation is simply exposing already-existing market volatility, adding transparency to the ETF’s price fluctuations. Much like our Asian equity ETF example above, the ETF didn’t increase the volatility of the local market, it just showed you where that market was valued even when it was closed. At the end of the day, a stock is worth what it’s worth and a bond is worth what it’s worth. ETFs are going to trade at a price that reflects where you can trade in the ETF’s underlying market. They simply reflect prices-they don’t cause them to move. A Look at Bond ETFs If we shift from stocks to bonds and look at fixed income ETFs, we must consider two things: first, that an ETF is a portfolio that trades intraday; and second, that it’s difficult to see intraday transactions in the bond market. Most investors have difficulty seeing bond price movements intraday; there is no ticker tape you can look to, and most data sources are delayed or hard to access. But if you have a bond ETF, the dynamic changes: The nature of this investment allows you to see price fluctuations intraday. A great example of this is “Taper Tantrum” that began in May 2013. Interest rates in the U.S. spiked suddenly at this time, and a lot of different bond investments dropped in price, high-yield ETFs included. Investors who were holding high-yield ETFs wondered why the price was falling. A quick look at the high-yield ETF market revealed that other high yield ETFs were dropping in price. If you could look at high yield bond trades you would have seen that they were declining as well. Most investors couldn’t see both the high yield bond market and the ETF market, but if they could they would see that the high yield ETF was reflecting the price drops in individual high yield bond trades. It’s not that the ETFs caused the dip; it’s that their prices simply reflected what was already there, but hidden. And this is another form of price discovery. The bond market and the bond ETF are both trading at the same time, but one is hard to see while the other is more visible. The ETF helps investors discover what is really happening in fixed income markets throughout the day. What are your questions about ETFs and volatility? Ask them here. This post originally appeared on the BlackRock Blog.

Why The World Appears More Uncertain

Why the World Appears More Uncertain In Image 1 , you will see the counties in the lowest decile of the kidney cancer distribution. As soon as we see an image like this, our brains immediately set about the task of explaining why it is that the healthy counties appear to be mainly rural. Perhaps it is a result of breathing in unpolluted air, consumption of fresh food delivered straight from the farm to the table, or maybe it’s the availability of clean water delivered by tranquil streams. As it turns out, the explanation has nothing to do with the environment or lifestyle, but I’ll come back to this in a moment. A young auto racing team has had a phenomenal year, finishing in the top five in 12 of the 15 races it completed. Unfortunately, the car failed to finish due to a blown engine in the other 7 outings. A decision needs to be made whether or not to enter the final race of the season on this particularly cold morning. Several major sponsors have taken notice of their performance and the team is on the cusp of moving from struggling upstart to a power player with significant financial resources. If they finish in the top 5 again today, they will certainly hit the tipping point to success. However, another blown engine will likely send them back to square one, or worse. Their engine mechanic, a true “grease monkey” believes the problem has something to do with ambient air temperature, but the chief mechanic, an engineer, disagrees. As proof, he provides the air temperature for each race in which they experienced a blown gasket, highlighting the fact that the problems occurred across a full range of temperatures (see Figure 1 ). More on their decision in a bit. Baseball has just entered the postseason, that moment when the 30 teams that have been competing to win the World Series are reduced to the top 8. It’s also the time when experts begin making predictions. As it is with all sports, the experts place great emphasis on momentum, particularly recent momentum. As an example, here is how one article on SBNation.com begins. “Rule No. 1 of predicting the postseason: Pick a very strong team. The Blue Jays are rolling. They have the best team, clearly.” It isn’t just the “experts” though. We all do it. For instance, if you were attempting to predict the outcome of the very next at-bat for a major league baseball player, which of the following do you believe would offer the most predictive value? His batting average over the last five plate appearances His batting average over the last five games His batting average over the last month His batting average over the season so far His batting average over the previous two seasons If you’re like most people, you would order the predictive power exactly as it is above. However when Moskowitz and Wertheim studied all MLB hitters over an entire decade, it was the batting average of the previous two seasons that offered the most predictive value. In fact, if you wanted to order the list above from most valuable to least in predicting the outcome of a batter’s next time at the plate, you’d need to flip it completely. Interestingly, they found the same results when applied to the NBA, NFL, NHL and European Football. Let’s return back to the question facing the owners of that auto racing team. Unfortunately, because the chief mechanic had framed the data in a narrow way, the key decision makers hadn’t thought to ask the simple, but important follow up question, “What were the temperatures when the engine did not fail?” Had they done so, they would have quickly discovered that temperature was indeed a key factor in the failures. Truth is, the story of the racing team as presented here is a fictitious one, created by Jack Brittain and Sim Sitkin as a case study for decision making. However, the data provided and the decision of “Go” or “No Go” was a very real one faced by the engineers at NASA ahead of the launch of the space shuttle, Challenger. Unfortunately for all involved, because the problem was initially framed very narrowly, some rather informative data, the kind that surely would have resulted in a “No Go” decision on that cold morning (see Figure 2 ), was missed. This is such a powerful story, because it shows that even the smartest among us are vulnerable to poorly framed problems resulting in all the difficulties that come with overvaluing small sample sets. Truth is, the annals of history are littered with similar mistakes by equally intelligent, educated and successful individuals, which is why it shouldn’t be hard to believe that this same mistake is made on a regular basis by professional investors, including the most successful ones. Let’s return to where we started this edition, by contemplating why it is that rural living results in lower incidents of kidney cancer , but first, some additional information before we get too deep in the creation of an intelligent sounding narrative. Image 2 shows the counties in the top decile of the kidney cancer distribution. Once again, rural areas dominate. If you had been presented with this image first, you would likely have jumped to the conclusion that the high rates might be due to higher poverty rates, limited access to proper medical care, greater propensity for smoking and drinking alcohol, or perhaps diets that tend to be higher in fats. The truth is, there is no valid narrative that can accurately explain the phenomenon. It is merely a function of studying a small sample set, but rather than chalk it up to the random, highly variable nature of small sample sets, we intuitively set about the task of generating a story that can explain it. Unfortunately for us, regardless of what we desire, small towns represent small sample sets and small sample sets typically exhibit greater variability and so tend to be overrepresented in the tails, both of them. It really is that simple. Back in 1984, a little known paper was written by Robert Abelson of Yale University where he proved mathematically that the percentage of variance in any single batting performance for major league baseball players explained by skill is less than one third of 1%. The author’s hypothesis, which led to the proof was that “many games are decided by freaky and unpredictable events such as windblown fly balls, runners slipping in patches of mud, baseballs bouncing oddly off outfield walls, field goal attempts hitting the goalpost, and so on… The ordinary mechanics of skilled actions such as hitting a baseball are so sensitive that the difference between a home run swing and a swing producing a pop up is so tiny as to be unpredictable, thus requiring it to be considered in largely chance terms.” While proving that skill played a minuscule role in an individual swing and at-bat, he did acknowledge that over sufficiently lengthy periods, skill was indeed a significant factor. Considering the high degree of variability and uncertainty inherent in very short term results, not to mention the volumes of research proving that small sample sets are more volatile, less predictable and less informative, it should make you question the decision making ability of portfolio managers, CIO’s and asset allocators who, in the face of turmoil and uncertainty, actually shorten their investment horizon. Although it appeals to our intuition and therefore feels right, focusing on progressively shorter term price action in order to gain greater control of your p&l volatility is quite simply, irrational. By shortening your time horizon, allowing both short-term price action and every individual data point, including non-farm payrolls, to drive your investment decisions, you are in fact increasing the influence of noise over signal, randomness over predictability, and injecting volatility into both your thought process, and results. Ironically, as more and more investors and their money managers attempt to reduce volatility and increase their sense of control by becoming hyper focused on what has just happened, their decisions become more sensitive to noise and their results more volatile. With this behavior having become so pervasive, it’s no wonder markets appear more volatile and less predictable these days. When you shift your focus away from the big picture, where trends are far more apparent and explicable, it’s only natural that the world would appear to be less certain, more volatile. The truth is, we can’t actually explain every tick in the S&P 500 or weekly move in wheat. In the scheme of things, these are little more than random events. When we continuously attempt to create seemingly coherent narratives to explain what are essentially random events, we will naturally experience more moments when our expectations are proven wrong than when we weren’t so myopic. Rather than accept responsibility for the mistake, we tend to place blame externally, which in this case leads to the explanation that the world no longer makes sense, that it is more volatile and uncertain. But, if we step back a bit, pull those charts back, consider what the really big forces are that are truly driving global economics and financial markets, we can see that the world hasn’t actually become more uncertain. The uncertainty is merely a function of how the problem is being framed, which is leading to poor decisions, lower returns and greater volatility, en masse. When that occurs, risk parameters tend to be tightened up even more, thereby exacerbating the problem, which is where we find ourselves today.